Elanco Animal Health (NYSE:ELAN) Announces Earnings Results, Beats Estimates By $0.07 EPS

Elanco Animal Health (NYSE:ELAN) issued its quarterly earnings results on Wednesday. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07, FiscalAI reports. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the previous year, the business earned $0.26 earnings per share. Elanco Animal Health’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health updated its Q3 2026 guidance to 0.190-0.220 EPS and its FY 2026 guidance to 1.100-1.160 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 8% organic constant-currency revenue growth in Q2, with U.S. pet health and U.S. farm animal each up 11%; adjusted EBITDA rose 21% and adjusted EPS increased 31% year over year.
• Strong demand for Zenrelia and Credelio Quattro drove innovation revenue to $340 million in the quarter, prompting the company to raise its 2026 innovation revenue target to approximately $1.25 billion.
• Elanco raised full-year guidance to 6%-7% organic constant-currency revenue growth, $1.01-$1.035 billion of adjusted EBITDA, and $1.10-$1.16 of adjusted EPS; it also lowered its expected year-end net leverage ratio to approximately three times.
• Zenrelia treated more than 2.5 million dogs, reached 47 countries, and achieved first-line use in more than 40% of users, while Quattro expanded to over half of U.S. veterinary clinics; Befrena demand is reportedly exceeding expectations, though supply is expected to remain constrained until early 2027.
• Elanco plans to increase operating expenses by investing in direct-to-consumer marketing and product launches, with Q3 expenses expected to rise about 11% in constant currency; management also cited ongoing inflation and a seasonally more second-half-weighted margin profile.

Elanco Animal Health Stock Up 2.3%

Shares of Elanco Animal Health stock traded up $0.60 during midday trading on Wednesday, hitting $26.20. The company’s stock had a trading volume of 13,856,909 shares, compared to its average volume of 5,401,829. The stock has a 50-day simple moving average of $24.68 and a 200-day simple moving average of $24.09. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $13.08 billion, a P/E ratio of -52.39, a PEG ratio of 1.68 and a beta of 1.67. Elanco Animal Health has a 1-year low of $13.76 and a 1-year high of $27.98.

Analyst Ratings Changes

A number of analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Morgan Stanley lifted their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.73.

Key Headlines Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported second-quarter adjusted EPS of $0.34, above the $0.27 analyst consensus and up from $0.26 a year earlier. Revenue rose 10.2% year over year to $1.368 billion, exceeding estimates of $1.31 billion, while organic constant-currency growth was 8%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 adjusted EPS guidance to $1.10-$1.16, above the $1.07 consensus, and increased revenue guidance to $5.09-$5.14 billion. Adjusted EBITDA guidance was raised to $1.01-$1.035 billion, implying 13% year-over-year growth at the midpoint. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: Elanco raised its 2026 innovation-revenue target to $1.25 billion, with Zenrelia reaching blockbuster-product status. Stronger newer-product performance supports the company’s growth narrative and likely drove investor optimism. Elanco Q2 2026 Earnings Call Transcript
• Positive Sentiment: Elanco improved its year-end net-leverage target to approximately 3.0 times adjusted EBITDA, versus 3.1 times at quarter-end, signaling continued progress on balance-sheet repair. Elanco Animal Health Reports Second Quarter 2026 Results
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion. The EPS range is generally in line with consensus, suggesting investors will look for further execution rather than an immediate forecast upgrade. Elanco Q2 Earnings and Revenues Beat Estimates
• Negative Sentiment: Reported net income was only $54 million, and Elanco continues to carry substantial leverage. Its reported net margin remained negative, leaving debt reduction and sustained product growth as important risks to the investment case.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi acquired 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of ELAN. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $41,000. Geneos Wealth Management Inc. boosted its position in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after acquiring an additional 2,080 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock worth $91,000 after acquiring an additional 1,332 shares during the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Elanco Animal Health by 31.9% in the fourth quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock worth $127,000 after acquiring an additional 1,358 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.